## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.2% in lower entry zone (3.0-6.0%), top 9% cross-sectional ranking. Short-term MRS_5 (1.6%) confirms momentum alignment. Outperforming sector by 3.3%. Caution: overbought RSI (71).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($190.63)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Charles River Laboratories stock hits 52-week high at $200.96 By Investing.com**
- Source: Investing.com Nigeria | 20251222T150819 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and a 33.65% 6-month price return. Despite current losses, analysts forecast profitability for FY2025, with several firms upgrading their ratings and price targets for the company.

**2. Charles River Laboratories stock hits 52-week high at $200.96**
- Source: Investing.com | 20251222T150801 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and outperforming with a 33.65% 6-month price return. Despite current losses, analysts forecast profitability for FY2025 with an EPS of $10.34, and the company has received multiple analyst upgrades and has concluded an SEC investigation with no enforcement action. This upward trajectory signals strong market interest and potential future gains for the pharmaceutical and biotechnology sector company.

**3. Charles River Laboratories stock hits 52-week high at $200.96 By Investing.com**
- Source: Investing.com Canada | 20251222T150634 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) has reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and a 33.65% 6-month price return. This surge comes amidst analyst upgrades and a concluded SEC investigation without enforcement action, indicating strong market confidence and potential for future growth in the pharmaceutical and biotechnology industries.

**4. Riverbridge Partners LLC Sells 8,323 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251222T124015 | Neutral | Relevance: 100%
- Riverbridge Partners LLC has reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by selling 8,323 shares, bringing its total ownership to 125,304 shares valued at approximately $19.6 million. Despite the sale, institutional investors and hedge funds still own 98.91% of the company's stock, with several firms increasing their positions. Analysts currently hold a "Moderate Buy" consensus rating for CRL with an average price target of $195.93.

**5. Thrivent Financial for Lutherans Acquires 20,172 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251222T100910 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by over 1,000%, acquiring an additional 20,172 shares, bringing their total to 22,176 shares valued at approximately $3.37 million. The medical research company recently exceeded EPS and revenue estimates, reporting $2.43 EPS against an expected $2.32 and $1.0 billion in revenue versus $990.4 million, despite a slight year-over-year revenue decline. Analysts maintain a "Moderate Buy" consensus rating for CRL, with institutional investors holding a substantial 98.91% of the company's stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 18.5x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $204.47 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 18.5 |
| Current P/E | 19.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 90th percentile. MRS_5 at 1.6% confirms short-term momentum alignment. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.15), confirming momentum. RSI overbought at 71, risk of mean reversion. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.18% (CS: 91) | Strong |
| RSI_14 | 70.9 | Overbought |
| MACD Histogram | 1.15 | Bullish |
| vs SMA20 | 1.082x | Above |
| vs SMA50 | 1.125x | Above |
| vs SMA200 | 1.288x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $202.83
- **Stop Loss:** $190.63 (6.0% risk)
- **Target:** $221.13 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 98
- **Position Value:** $19,877.34
- **Portfolio %:** 19.88%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*